A national survey of hospital-based transfusion services on their approaches to platelet bacterial risk mitigation in response to the FDA final guidance for industry.
Journal
Transfusion
ISSN: 1537-2995
Titre abrégé: Transfusion
Pays: United States
ID NLM: 0417360
Informations de publication
Date de publication:
08 2020
08 2020
Historique:
received:
06
03
2020
revised:
10
04
2020
accepted:
10
04
2020
pubmed:
22
6
2020
medline:
22
6
2021
entrez:
22
6
2020
Statut:
ppublish
Résumé
Bacterial contamination of platelets is the leading infectious risk to the United States (US) blood supply. On 30 September 2019, the US Food and Drug Administration (FDA) published a Final Guidance for Industry to reduce the risk of transfusing platelets contaminated by bacteria. A national survey was undertaken to assess readiness, attitudes, and the potential impact on hospital-based transfusion services. A survey was distributed to transfusion services in all 50 US states. Summary statistics were performed along with review and categorization of email feedback and free text comments. Eighty-three transfusion services from 48 states participated in this survey study. Currently, the most common approach is primary culture performed at manufacturing (n = 49/83, 59%). Of the bacterial risk mitigation strategies provided by the FDA, the most frequently preferred are (a) pathogen reduced platelets (PRP) for up to 5-day storage (n = 36/77, 47%), (b) large volume delayed sampling (LVDS) ≥48 hours for up to 7-day storage (n = 16/77, 21%), and (c) primary culture ≥24 hours + secondary rapid testing for up to 7-day storage (n = 7/77, 9%). The main motivating factors for the survey participants' selected strategies to comply with FDA final guidance were product availability from supplier, reducing the risk of septic transfusion reactions (STR), and complexity of implementing and performing a new or additional test. While having platelets to transfuse and preventing STR are of the utmost importance, nationwide, the majority of transfusion services do not want to take on performing new or additional testing in their laboratories.
Sections du résumé
BACKGROUND
Bacterial contamination of platelets is the leading infectious risk to the United States (US) blood supply. On 30 September 2019, the US Food and Drug Administration (FDA) published a Final Guidance for Industry to reduce the risk of transfusing platelets contaminated by bacteria. A national survey was undertaken to assess readiness, attitudes, and the potential impact on hospital-based transfusion services.
STUDY DESIGN AND METHODS
A survey was distributed to transfusion services in all 50 US states. Summary statistics were performed along with review and categorization of email feedback and free text comments.
RESULTS
Eighty-three transfusion services from 48 states participated in this survey study. Currently, the most common approach is primary culture performed at manufacturing (n = 49/83, 59%). Of the bacterial risk mitigation strategies provided by the FDA, the most frequently preferred are (a) pathogen reduced platelets (PRP) for up to 5-day storage (n = 36/77, 47%), (b) large volume delayed sampling (LVDS) ≥48 hours for up to 7-day storage (n = 16/77, 21%), and (c) primary culture ≥24 hours + secondary rapid testing for up to 7-day storage (n = 7/77, 9%). The main motivating factors for the survey participants' selected strategies to comply with FDA final guidance were product availability from supplier, reducing the risk of septic transfusion reactions (STR), and complexity of implementing and performing a new or additional test.
CONCLUSION
While having platelets to transfuse and preventing STR are of the utmost importance, nationwide, the majority of transfusion services do not want to take on performing new or additional testing in their laboratories.
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1681-1687Subventions
Organisme : None
Informations de copyright
© 2020 AABB.
Références
U.S. Food & Drug Administration. Bacterial risk control strategies for blood collection establishments and transfusion services to enhance the safety and availability of platelets for transfusion. https://www.fda.gov/media/123448/download. Accessed November 15, 2019.
Jones J, Sapiano MRP, Savinkina A, et al. Slowing decline in blood collection and transfusion in the United States - 2017. Transfusion. 2020;60:S1-S9.
U.S. Food & Drug Administration. INTERCEPT blood system for platelets. https://www.fda.gov/vaccines-blood-biologics/approved-blood-products/intercept-blood-system-platelets. Accessed March 27, 2020.
Devine DV, Schubert P. Pathogen inactivation technologies: the advent of pathogen-reduced blood components to reduce blood safety risk. Hematol Oncol Clin North Am. 2016;30:609-617.
Atreya C, Glynn S, Busch M, et al. Proceedings of the Food and Drug Administration public workshop on pathogen reduction technologies for blood safety 2018 (Commentary, p3026). Transfusion. 2019;59:3002-3025.
McDonald C, Allen J, Brailsford S, et al. Bacterial screening of platelet components by National Health Service Blood and Transplant, an effective risk reduction measure. Transfusion. 2017;57:1122-1131. https://doi.org/10.1111/trf.14085
Platelet Pan Genera Detection® (PGD). Test system package insert. Verax Biomedical Inc., Catalog Number: BK140201. https://www.fda.gov/media/104427/download. Accessed March 28, 2020.
Ruby KN, Thomasson RR, Szczepiorkowski ZM, et al. Bacterial screening of apheresis platelets with a rapid test: a 113-month single center experience. Transfusion. 2018;58:1665-1669.
Cid J. Prevention of transfusion-associated graft-versus-host disease with pathogen-reduced platelets with amotosalen and ultraviolet A light: a review. Vox Sang. 2017;112:607-613.
U.S. Food & Drug Administration. Recommendations for reducing the risk of transfusion-transmitted babesiosis. https://www.fda.gov/media/114847/download. Accessed March 28, 2020.
U.S. Food & Drug Administration. Revised recommendations for reducing the risk of Zika virus transmission by blood and blood components. https://www.fda.gov/media/92490/download. Accessed March 28, 2020.
AABB, Clinical Transfusion Medicine Committee, Heddle NM, Boeckh M, et al. AABB Committee Report: reducing transfusion-transmitted cytomegalovirus infections. Transfusion. 2016;56:1581-1587.
Sachias B, Paradiso S, Stauss D, et al. Implications of the US Food and Drug Administration draft guidance for mitigating septic reactions from platelet transfusions. Blood Adv. 2017;1:1142-1147.